Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multicenter phase II trial ALTER-G-001-cohort C

被引：0
|
作者：
Wu, J. [1 ]
Zhou, C. [1 ]
Yan, J. [2 ]
Han, Z. [3 ]
Wang, C. [2 ,5 ]
Qin, Z. [4 ]
Jiang, J. [1 ]
Wang, C. [2 ,5 ]
Tang, X. [6 ]
Zhu, L. [7 ]
Chen, J. [8 ]
Mao, Y. [9 ]
Wei, X. [10 ]
Shangguan, C. [1 ]
Zhang, J. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China
[2] Jiading Cent Hosp, Dept Oncol, Shanghai, Peoples R China
[3] Xuzhou Med Univ, Affiliated Hosp, Dept Oncol, Xuzhou, Jiangsu, Peoples R China
[4] Zhejiang Prov Peoples Hosp, Dept Oncol, Hangzhou, Peoples R China
[5] 3 Peoples Hosp Yancheng, Dept Oncol, Yancheng, Peoples R China
[6] Ruijin Hosp, Wuxi Branch, Dept Oncol, Wuxi, Jiangsu, Peoples R China
[7] Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China
[8] Ningbo Univ, Affiliated Peoples Hosp, Dept Oncol, Ningbo, Peoples R China
[9] Jiangnan Univ, Wuxi Peoples Hosp 4, Dept Oncol, Wuxi, Jiangsu, Peoples R China
[10] Nanjing First Hosp, Dept Oncol, Nanjing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.285
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
150P
引用
收藏
页码：S1533 / S1533
页数：1
相关论文
共 50 条
  • [41] CETUFTIRI, a new combination of UFT with leucovorin (LV), irinotecan, and cetuximab as first-line treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Preliminary results from a multicenter phase II trial
    Bennouna, J.
    Faroux, R.
    Francois, E.
    Ligeza, C.
    El Hannani, C.
    Perrier, H.
    Jacob, J.
    Desseigne, F.
    Perrocheau, G.
    Douillard, J. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] Vibostolimab coformulated with pembrolizumab (vibo/ pembro) plus chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study
    Hsu, C-H.
    Dziadziuszko, R.
    Gomez Abreo, D. A.
    Aksoy, S.
    Gil Martin, M.
    Roderburg, C.
    Yen, C. J.
    Arican, A.
    Cassier, P.
    Im, S-A.
    Kim, S-B.
    Kudo, T.
    Ochsenreither, S.
    Sendur, M. A. N.
    Yonemori, K.
    Rojas, C. I.
    Liu, Q.
    Keenan, T.
    Healy, J.
    Kwiatkowski, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S163 - S164
  • [43] Updated results and biomarker analyses from the phase 2 trial (BBCAPX study) of sintilimab plus bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer
    Yuan, Ying
    Fang, Xuefeng
    Zhu, Ning
    Zhong, Chenhan
    Wang, Liu-Hong
    Li, Jun
    Weng, Shanshan
    Hu, Hanguang
    Dong, Caixia
    Li, Dan
    Song, Yongmao
    Xu, Dong
    Wang, Jianwei
    Sun, Lifeng
    Wang, Jian
    Liao, Xiujun
    Yu, Ningjuan
    Zhang, Suzhan
    Ding, Ke-Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first-line therapy for advanced or metastatic gastric or gastroesophageal junction cancer: Updated results from a multicenter, open label phase II trial.
    Shen, Lin
    Peng, Zhi
    Zhang, Yan-Qiao
    Wei, Jia
    Wang, Feng
    Ying, Jieer
    Deng, Yanhong
    Gu, Kangsheng
    Cheng, Ying
    Yuan, Xianglin
    Xiao, Juxiang
    Wang, Linna
    Zou, Jianjun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] Preliminary results of benmelstobart plus anlotinib combined with SOX in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with low PD-L1 expression: A single-arm, multicenter phase II clinical trial
    Jia, Yong-Xu
    Chang, Zhiwei
    Zhong, Ya-Li
    Cui, Donghai
    Han, Hui-Qiong
    Gao, Ya-Ping
    He, Jian
    Liu, Xiao-Lei
    Yan, Jie
    Qin, Yanru
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 444 - 444
  • [46] Updated results from ALTER-H004 trial: Anlotinib combined with TACE as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgery-A single arm, multi-center, phase II clinical trial
    Wu, Zheng
    Wang, Zheng
    Zhang, Lei
    Song, Xiaojing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Capecitabine (X) plus gemcitabine (G) as first-line treatment in patients (pts) with locally advanced/metastatic pancreatic cancer: preliminary results from an open-label, multicenter phase II study
    Song, Hong Suk
    Do, Young Rok
    Chang, Heung Moon
    Ryu, Min Hee
    Lee, Kyung Hee
    Kim, Yeul Hong
    Hong, Dae Sik
    Cho, Jae Yong
    Lee, Kyoung Eun
    Kim, Si Young
    ANNALS OF ONCOLOGY, 2004, 15 : 243 - 243
  • [48] First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab (P) in patients with locally advanced or metastatic cancer of the stomach or gastro-esophageal junction: Updated results of a phase II multicenter trial
    Tomasello, Gianluca
    Liguigli, Wanda
    Toppo, Laura
    Negri, Federica
    Curti, Alessandra
    Ratti, Margherita
    Poli, Rossana
    Lazzarelli, Silvia
    Gerevini, Fabiana
    Colombi, Chiara
    Rovatti, Massimo
    Olivetti, Lucio
    Martinotti, Mario
    Passalacqua, Rodolfo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
    Ooki, Akira
    Morita, Satoshi
    Tsuji, Akihito
    Iwamoto, Shigeyoshi
    Hara, Hiroki
    Tanioka, Hiroaki
    Satake, Hironaga
    Kataoka, Masato
    Kotaka, Masahito
    Kagawa, Yoshinori
    Nakamura, Masato
    Shingai, Tatsushi
    Ishikawa, Masashi
    Miyake, Yasuhiro
    Suto, Takeshi
    Hashiguchi, Yojiro
    Yabuno, Taichi
    Ando, Masahiko
    Sakamoto, Junichi
    Yamaguchi, Kensei
    CANCER MEDICINE, 2020, 9 (24): : 9419 - 9430
  • [50] A randomized phase II multi-institutional trial of anlotinib plus docetaxel versus docetaxel in EGFR-wild-type non-small cell lung cancer (NSCLC) patients after progression on first-line platinum-base chemotherapy: ALTER-L018.
    Wu, Lin
    Wu, Zhijun
    Xiao, Zemin
    Weng, Jie
    Ma, Zhongsha
    Chen, Yanhua
    Xiao, Maoliang
    Cao, Yongqing
    Duan, Huaxin
    Cao, Peiguo
    Zhang, Hui
    Wang, Qianzhi
    Li, Jia
    Xu, Yan
    Pu, Xingxiang
    Li, Kang
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345